Brain/CNS Clinical Trials

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Genomically-Guided Treatment Trial in Brain Metastases

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

A Phase II Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Age - Patients must be Greater than or Equal to 3 Years and Less than 22 Years of Age at the Time of Enrollment on ACNS1422 Step 0.

A Phase II Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation,Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations

Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.

Patients >21 Years must be IDH Mutant.

Note: At the time of ACNS1721 Step 1 enrollment, patients will be stratified and age is a factor.

A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.

A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in 
Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Patients must be ≥ 2 Years and ≤ 21 Years at the Time of Enrollment.

ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment on ACNS1833 Step 0.

Neuroblastoma Biology Studies

All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study. 

COG-ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Feasibility Phase - Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≥ 2 years and ≤ 25 years of age at the time of enrollment.
All patients > 21 years of age at the time of enrollment must have had initial diagnosis of low-grade glioma by 21 years of age.